| paricalcitol / Generic mfg. |
NCT00428246: Study of Protective Effects of Paricalcitol on Inner Layer of Vessels and Its Protective Effect on Inflammation |
|
|
| Completed | N/A | 24 | US | paricalcitol, Zemplar, Placebo | Indiana University School of Medicine, Abbott | Chronic Kidney Disease, Endothelial Dysfunction, Inflammation, Hypertension | 07/07 | 07/07 | | |
NCT00469625: A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease |
|
|
| Withdrawn | N/A | 0 | US | paricalcitol (initial dose 1 mcg orally per day) | Winthrop University Hospital | Proteinuric Renal Disease | 01/08 | 01/08 | | |
NCT00800358: Safety and Efficacy Study of Paricalcitol Versus Calcitriol in the Treatment of Secondary Hyperparathyroidism |
|
|
| Completed | N/A | 69 | RoW | Paricalitol, Zemplar, Calcitriol | Penang Hospital, Malaysia, Ministry of Health, Malaysia | Hyperparathyroidism, Kidney Disease | 10/09 | 12/09 | | |
NCT01084538: Study of Zemplar iv in Patients With End Stage Chronic Kidney Disease, Undergoing Haemodialysis |
|
|
| Completed | N/A | 181 | RoW | Zemplar iv (paricalcitol iv), Zemplar iv | Abbott | Parathyroid Hormone | 06/10 | 06/10 | | |
NCT02378805: European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome |
|
|
| Recruiting | N/A | 500 | Europe | ACE-inhibitor, Ramipril, AT1-inhibitor, HMG-Coenzyme inhibitor (statin), Spironolactone, Paricalcitol, SGLT2 inhibitor | University Hospital Goettingen, Society for Pediatric Nephrology (Germany), Deutsche Gesellschaft für Nephrologie, Alport Selbsthilfe e.V., Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG), KfH Foundation Preventive Medicine | Alport Syndrome, Hereditary Kidney Disease, Pediatric Kidney Disease, Thin Basement Membrane Disease, Familial Benign Hematuria | 07/10 | 01/35 | | |
| Terminated | N/A | 86 | Europe | paricalcitol, Zemplar, alfacalcidol | Zealand University Hospital | Secondary Hyperparathyroidism, Chronic Kidney Disease, Vitamin D Deficiency | 09/10 | 10/10 | | |
NCT01081665: Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism |
|
|
| Completed | N/A | 237 | Europe | | Abbott | Chronic Kidney Failure, Secondary Hyperparathyroidism | 02/11 | 02/11 | | |
NCT00915876: Vascular Reactivity in Chronic Kidney Disease (CKD) Patients Receiving Paricalcitol Versus Placebo |
|
|
| Completed | N/A | 41 | US | Paricalcitol, Placebo | Amy Barton Pai, Albany College of Pharmacy and Health Sciences | Chronic Kidney Disease | 03/11 | 03/11 | | |
NCT00796679: Oral Paricalcitol in Stage 3 - 5 Chronic Kidney Disease |
|
|
| Completed | N/A | 60 | RoW | paricalcitol, Zemplar | The University of Hong Kong, Abbott | Chronic Kidney Disease | 06/11 | 06/11 | | |
|
NCT00587158: Oral Paricalcitol in Kidney Transplant Recipients |
|
|
| Completed | N/A | 100 | US | Paricalcitol, Brand name is Zemplar®, Corticosteroid Avoidance Immune Suppression Protocol, Standard Immune Suppression | Mayo Clinic, Abbott | Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary | 11/11 | 11/11 | | |
NCT01273597: Observational Study to Evaluate the Time to Achieving the Maintenance Dose of Zemplar® (Paricalcitol Injection) in the Treatment of Patients Suffering From End-stage Renal Disease and Severe Over-reactivity of the Parathyroid Glands |
|
|
| Completed | N/A | 60 | Europe | | AbbVie (prior sponsor, Abbott), Planimeter Ltd | Kidney Failure, Chronic | 11/11 | 11/11 | | |
| Completed | N/A | 500 | Europe | | AbbVie (prior sponsor, Abbott) | Chronic Kidney Failure, Secondary Hyperparathyroidism | 01/12 | 01/12 | | |
NCT01134315: Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice |
|
|
| Terminated | N/A | 61 | US | Paricalcitol, ABT-358, Zemplar, Calcitriol | AbbVie (prior sponsor, Abbott), North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS) | Secondary Hyperparathyroidism, End-Stage Renal Disease | 05/12 | 05/12 | | |
NCT02018133: Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients |
|
|
| Completed | N/A | 8 | US | Vitamin D 2mg daily for 2 weeks oral paricalcitol, Zemplar, Placebo | University of Illinois at Chicago, Abbott | CKD Stage 3/4 | 06/12 | 06/12 | | |
NCT01792206: Effect Of Paricalcitol (Zemplar) On Endothelial Function And Inflammation In Type 2 Diabetes And Chronic Kidney Disease |
|
|
| Unknown status | N/A | 60 | US | Zemplar, Placebo | Scott and White Hospital & Clinic, Abbott | Type 2 Diabetes, Chronic Kidney Disease | 11/12 | 02/13 | | |
CAPITOL, NCT01265992: Study to Assess Patient Management Practices and Quality of Life With Paricalcitol Capsules in the Treatment of Secondary Hyperparathyroidism in Stage 3-5 Chronic Kidney Disease Patients Not Yet on Dialysis |
|
|
| Completed | N/A | 50 | Europe | | AbbVie (prior sponsor, Abbott), Pharma Consulting Group AB | Secondary Hyperparathyroidism, Chronic Kidney Disease | 11/12 | 11/12 | | |
NCT01401478: Observational Program of Zemplar in Patients With End Stage Chronic Kidney Disease and Parathyroid Disorder on Hemodialysis in the Russian Federation |
|
|
| Completed | N/A | 86 | RoW | | AbbVie (prior sponsor, Abbott), Almedis | Secondary Hyperparathyroidism | 01/13 | 01/13 | | |
NCT01073462: Study to Evaluate the Effect of Intravenous (IV) Paricalcitol (Zemplar) on Cardiac Morbidity in Patients With Chronic Kidney Disease (CKD) Stage 5 Over 2 Years |
|
|
| Completed | N/A | 67 | Europe | | AbbVie (prior sponsor, Abbott), Assign Data Management and Biostatistics GmbH | Secondary Hyperparathyroidism, Chronic Kidney Disease Stage V, Cardiac Morbidity | 06/13 | 06/13 | | |
| Completed | N/A | 265 | Europe | | AbbVie (prior sponsor, Abbott) | Chronic Kidney Disease, Secondary Hyperparathyroidism | 06/13 | 06/13 | | |
NCT01224782: Evaluation of Treatment With Zemplar Capsules in the Therapy of Secondary Hyperparathyroidism (SHPT) |
|
|
| Completed | N/A | 994 | Europe | | AbbVie (prior sponsor, Abbott) | Chronic Kidney Disease, Secondary Hyperparathyroidism | 08/13 | 08/13 | | |
NCT01758289: Post Marketing Observational Study on Paricalcitol IV Administered to Venezuelan Patients |
|
|
| Terminated | N/A | 105 | RoW | | AbbVie (prior sponsor, Abbott) | Chronic Kidney Disease Stage V, Hemodialysis | 11/13 | 11/13 | | |
TOP, NCT01083849: Long-Term Therapy Outcomes When Treating Chronic Kidney Disease (CKD) Patients With Paricalcitol in German and Austrian Clinical Practice |
|
|
| Completed | N/A | 761 | Europe | | AbbVie (prior sponsor, Abbott) | Kidney Insufficiency, Secondary Hyperparathyroidism | 12/13 | 12/13 | | |
| Completed | N/A | 14 | Europe | Paricalcitol | Federico II University | Fabry Disease, Proteinuria | 12/13 | 12/13 | | |
| Withdrawn | N/A | 0 | US | Paricalcitol, Zemplar® | Massachusetts General Hospital | Heart Failure | 05/14 | 06/14 | | |
NCT02273570: Optimal Anemia Treatment in End Stage Renal Disease (ERSD) |
|
|
| Unknown status | N/A | 50 | Europe | standard care, Drugs available on the market control iPTH, Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D | Azienda Ospedaliera Sant'Anna, Amgen | Hyperparathyroidism, Secondary | 12/16 | 03/17 | | |
ChiCTR1900025628: A study for percutaneous paricalcitol injection in the treatment of chronic kidney disease associated tertiary hyperparathyroidism |
|
|
| Not yet recruiting | N/A | 30 | | percutaneous paricalcitol injection | West China Hospital, Sichuan University; West China Hospital, Sichuan University, none | chronic kidney disease associated tertiary hyperparathyroidism | | | | |
ChiCTR2100046642: The effect of paricalcitol injection on secondary hyperparathyroidism in hemodialysis patients |
|
|
| Recruiting | N/A | 360 | | Paricalcitol treatment | Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine; Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Corporate Sponsor | Secondary hyperparathyroidism | | | | |
NCT06126016: A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj. |
|
|
| Recruiting | N/A | 1000 | RoW | | Boryung Pharmaceutical Co., Ltd | Chronic Kidney Disease 5D, Secondary Hyperparathyroidism | 04/26 | 04/26 | | |
NCT06209268: The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients |
|
|
| Not yet recruiting | N/A | 90 | NA | Paricalcitol injection, Placebo | University of Split, School of Medicine | Sepsis | 12/24 | 02/25 | | |
ChiCTR2200065308: Effect of radiofrequency parathyroid ablation versus local injection of Paricalcitol in the treatment of secondary hyperparathyroidism in chronic kidney disease: a multicenter, randomized, controlled trial |
|
|
| Not yet recruiting | N/A | 60 | | radiofrequency ablation ;local injection of Paricalcitol | The Second Affiliated Hospital, Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Self-financed | secondary hyperparathyroidism | | | | |
